3692.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 10:08):

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China...

Stats
Tagesvolumen	6.48M
Durchschnittsvolumen	5.62M
Marktkapitalisierung	103.65B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0.0707 ( 2023-09-15 )
Next Dividend	HKD0 ( N/A )
P/E	31.21
ATR14	HKD0.0180 (0.10%)

Volumen Korrelation

Lang: 0.04 (neutral)

Kurz: -0.52 (weak negative)

Signal:(69.894) Neutral

Hansoh Pharmaceutical Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Hansoh Pharmaceutical Korrelation - Währung/Rohstoff

-0.34
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.58
( weak negative )

-0.18
( neutral )

0.70
( moderate )

Hansoh Pharmaceutical Finanzdaten

Annual	2023
Umsatz:	HKD10.10B
Bruttogewinn:	HKD9.07B (89.78 %)
EPS:	HKD0.520

FY	2023
Umsatz:	HKD10.10B
Bruttogewinn:	HKD9.07B (89.78 %)
EPS:	HKD0.520

FY	2022
Umsatz:	HKD9.38B
Bruttogewinn:	HKD8.51B (90.73 %)
EPS:	HKD0.440

FY	2021
Umsatz:	HKD9.94B
Bruttogewinn:	HKD9.07B (91.24 %)
EPS:	HKD0.460

Financial Reports:

No articles found.

Hansoh Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0500 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0500 (N/A)	HKD0.141 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Hansoh Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.64 - Stable (32.86%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0771	2021-06-07
Last Dividend	HKD0.0707	2023-09-15
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.576	--
Avg. Dividend % Per Year	0.00%	--
Score	3.76	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.64
Div. Directional Score	8.95	--

Next Divdend (Est)
(2024-09-27)

HKD0.0743 Estimate 11.67 %

Dividend Stability

0.47 Below Average

Dividend Score

3.76

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3326.HK	Ex Dividend Knight	2023-06-07	Annually	0.00%
1553.HK	Ex Dividend Junior	2023-06-09	Annually	0.00%
0595.HK	Ex Dividend Junior	2023-09-06	Annually	0.00%
9616.HK	Ex Dividend Junior	2023-08-07	Annually	0.00%
2119.HK	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
1120.HK	Ex Dividend Knight	2023-06-12	Annually	0.00%
0207.HK	Ex Dividend Junior	2023-06-12	Sporadic	0.00%
3818.HK	Ex Dividend Knight	2023-08-21	Annually	0.00%
1709.HK	No Dividend Player	2023-09-13	Annually	0.00%
0737.HK	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.324	1.500	3.51	5.27	[0 - 0.5]
returnOnAssetsTTM	0.0992	1.200	6.69	8.03	[0 - 0.3]
returnOnEquityTTM	0.131	1.500	9.65	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.21	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.02	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.27	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.130	-1.500	7.84	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.160	2.00	9.92	10.00	[0 - 20]
debtEquityRatioTTM	0.166	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.898	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.265	1.000	6.70	6.70	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.267	1.000	9.63	9.63	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.295	-1.036	[0.5 - 2]
Total Score				11.25

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	33.03	1.000	6.76	0	[1 - 100]
returnOnEquityTTM	0.131	2.50	9.78	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.160	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	1.166	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	4.64	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.113	1.000	9.66	0	[0.1 - 0.5]
Total Score				6.64

Hansoh Pharmaceutical

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.